Navigation Links
IFRS Information - First Half of 2007
Date:9/13/2007

w River Collaboration Agreements, the parties were required to collaborate on the development, manufacturing, marketing and sales of VYVANSE in the US. Profits from the collaboration arising in the US were to be divided according to a predetermined formula, based on the scheduling of VYVANSE by the DEA. Post-approval milestones were due under the New River Collaboration Agreements if the product received favorable scheduling (schedule III, IV or V or unscheduled) and on the achievement of certain sales milestones.

Through the New River Collaboration Agreements Shire also acquired the license in the RoW territory to develop and commercialize VYVANSE, in consideration of a low double-digit royalty.

Shire paid an initial sum of $50 million to New River in January 2005 on signing the original collaboration agreement and a further $50 million was paid by Shire to New River following acceptance of the filing of a New Drug Application ("NDA") by the FDA in January 2006. These payments were capitalized by the Company as intangible assets in accordance with IAS 38, "Intangible Assets". As at the acquisition date, no amortization had been recorded in respect of these intangible assets as they were not yet available for use as final DEA scheduling was yet to be received.

As Shire has a pre-existing relationship with New River, Shire has accounted for the acquisition of New River as a multiple element transaction, with one element being the business combination and one element being the effective settlement of Shire's pre-existing relationship with New River. As no specific guidance exists under IFRS 3 `Business Combinations' governing the accounting for business combinations when a pre-existing relationship is present, Shire has analogised the multiple element approach as outlined in IAS 18, "Revenue", together with specific guidance in US GAAP in respect of accounting for business combinations when pre-existing relationships exist as outlined in EITF 04-1, "
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Imaging and Analysis of DIGE Product Information Sheet, Rev B
2. Study affirms information technology-productivity link
3. TrafficCast integrates new information source
4. Rote education fails the Information Age
5. Weather information companies launch data product
6. TeraMedica launches information manager
7. Global information firm reaches diverse markets
8. Preparing for avian flu with information technology
9. Businesses cant hide personal information losses, theft
10. S.C. Johnson lands in No. 2 spot in Information Week 500 list
11. Crate and Barrel deploys Firstlogics Information Quality Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the six ... otherwise, are expressed in Canadian dollars and presented ... Second Quarter 2014 Highlights , Announced ... acuity (VA) primary endpoint for subjects enrolled in ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., the ... alcohol-based hand sanitizer, asks food processors and food handling ... hand sanitizer they’re currently using to Best Sanitizers’ ... is critical to fighting cross-contamination and the spread of ... believes there are key criteria that make a hand ...
(Date:8/28/2014)... , Aug. 28, 2014 ... a new market research report ... Whole Exome Sequencing ... (Library Preparation, Target Enrichment), by ... by Synthesis), by Application (Cancer, ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... quarter and year ended December 31, 2008. , "During ... Products Business and were able to sustain progress on ... year for TAXUS," said Dr. William Hunter, President and ...
... Elite MPX(TM): Powerful Multi-Wavelength Workstation Combines ... in a Single System- SmartSense(TM) with ThermaGuide(TM): ... First Intelligent Delivery System for LaserBodyContouring- ThermaView(TM): ... Combination of Enhanced Safety and Control for ...
... Inc. (NYSE Alternext US: PTN) reported that its exchange ... been accepted by the NYSE Alternext US LLC (the ... reported on December 30, 2008, Palatin received notice from ... certain continued listing requirements under Sections 1003(a)(ii) and (iii) ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008 28Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting 2Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting 3Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting 4Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting 5Palatin Technologies' Listing Compliance Plan Accepted by NYSE Alternext US 2
(Date:9/1/2014)... in the U.S. undergoes a battery of tests designed ... disease. Thousands of children born in the developing world, ... from the disease each year. , A.J. Kumar ... of those deaths. , A Post-Doctoral Fellow in ... George Whitesides, the Woodford L. and Ann A. Flowers ...
(Date:9/1/2014)... decisions of the Nomenclature Section of the XVIII International ... 2011. This meeting is held every six years and ... rules for naming algae, fungi and plants get together ... the organisms they study. This is the primary product ... algae, fungi, and plants, which was published in 2012. ...
(Date:8/31/2014)... When they are not busy attacking us, germs go ... doesn,t always spell disaster for the infected microbes: Sometimes ... harness to, say, expand its diet or better attack ... version of an immune system would robotically destroy anything ... at Rockefeller University have now revealed that one variety ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3
... A new poisonous frog was recently discovered in a ... young scientists supported by the Conservation Leadership Programme (CLP). ... length, was given the name the ?golden frog of ... was similar to several other common species in the ...
... in the Western world. The tumor starts off as a ... which often spreads to the liver. In an article recently ... Dr. Nancy Gavert of the Weizmann Institutes Molecular Cell Biology ... a majority of cases, colorectal cancer is initiated by changes ...
... ever discovered DNA from living bacteria that are more than ... still living organisms that old been found. The exceptional discovery ... cells and might even cast light on the question of ... current issue of PNAS (Proceedings of The National Academy of ...
Cached Biology News:A gene for metastasis 2The world's oldest bacteria 2
...
Request Info...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... supernates and serum. Each kit contains sufficient ... 96-well plates, provided that the following conditions ...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Biology Products: